Mesothelioma epidemiology and demographics
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Fatima Shaukat, MD [2]Parminder Dhingra, M.D. [3], Sujit Routray, M.D. [4]
Overview
Overview
Mesothelioma is a rare disease which accounts for 5-28% of all malignancies that involve the pleura. The incidence of mesothelioma is estimated to be 3,000 cases annually. The incidence of pleural mesothelioma is approximately 1 per 100,000 individuals in the United States. Males are more commonly affected with mesothelioma than females. The male to female ratio is approximately 3 to 1. The incidence of mesothelioma increases with age; the median age at diagnosis for pleural mesothelioma and peritoneal mesothelioma are 74 years and 68 years, respectively. There is no racial predilection to mesothelioma.
Epidemiology and Demographics
Epidemiology and Demographics
Prevalence
- Mesothelioma is a rare disease which accounts for 5-28% of all malignancies that involve the pleura.[1]
Incidence
- The incidence of mesothelioma is estimated to be 3,000 cases annually.[2]
- The incidence of pleural mesothelioma is approximately 1 per 100,000 individuals in the United States.[3]
- The incidence of pleural mesothelioma is approximately 1.2 per 100,000 individuals in Canada.[3]
- The incidence of mesothelioma has decreased over several decades in the United States coincident with diminishing occupational asbestos exposure and has remained stable since 2003.[4]
Age
- Males are more commonly affected with mesothelioma than females. The male to female ratio is approximately 3 to 1.[1]
- The incidence of mesothelioma increases with age; the median age at diagnosis for pleural mesothelioma and peritoneal mesothelioma are 74 years and 68 years, respectively.[4]
Race
- There is no racial predilection to mesothelioma.[1]
References
References
- ↑ 1.0 1.1 1.2 Epidemiology of mesothelioma. Dr Bruno Di Muzio and A.Prof Frank Gaillard et al. Radiopaedia 2016. http://radiopaedia.org/articles/mesothelioma. Accessed on February 8, 2016
- ↑ Philip A. Rascoe, Xiaobo X. Cao and W. Roy Smythe (2012). Molecular Pathogenesis of Malignant Pleural Mesothelioma, Mesotheliomas – Synonyms and Definition, Epidemiology, Etiology, Pathogenesis, Cyto-Histopathological Features, Clinic, Diagnosis, Treatment, Prognosis, Dr Alexander Zubritsky (Ed.), ISBN: 978-953-307-845-8, InTech, Available from: http://www.intechopen.com/books/mesotheliomas-synonyms-and-definition-epidemiology-etiology-pathogenesis-cyto-histopathological-features-clinic-diagnosis-treatment-prognosis/molecular-pathogenesis-of-malignant-pleural-mesothelioma
- ↑ 3.0 3.1 Saint-Pierre, Mathieu D.; Pease, Christopher; Mithoowani, Hamid; Zhang, Tinghua; Nicholas, Garth A.; Laurie, Scott A.; Wheatley-Price, Paul (2015). “Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate Antimetabolite Chemotherapy”. Lung Cancer International. 2015: 1–7. doi:10.1155/2015/590148. ISSN 2090-3197.
- ↑ 4.0 4.1 Thomas, Anish; Chen, Yuanbin; Yu, Tinghui; Gill, Ammara; Prasad, Vinay (2015). “Distinctive clinical characteristics of malignant mesothelioma in young patients”. Oncotarget. 6 (18): 16766–16773. doi:10.18632/oncotarget.4414. ISSN 1949-2553.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH